Are you a hematologist or oncologist treating patients with multiple myeloma? If so, this half-day workshop is for you.
This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
At the conclusion of this educational activity, you will be able to: 1. Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy. 2. Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies. 3. Understand toxicities and their management post-novel immune strategies.